Negotiating the Emerging Biosimilars Landscape: Key developments in the regulatory environment

As regulatory obstacles to biosimilars development have become increasingly resolved, a growing number of opportunities have been created for generics companies in the biopharmaceutical market, which according to IMS data was valued at $85.9 billion in 2007. Conservative projections estimate that sales of biopharmaceutical products will exceed $135 billion by 2011.

Read more...

• Emerging Biosimilars Landscape (21/01/2010)
• Emerging Clinical Trial Locations (21/01/2010)
• Croatia - Pricing and Reimbursement News (21/07/2009)

• Biosimilars-Regulatory Issues (27/05/2008)
• Innovation in Drug Delivery (15/05/2008)
• Winning Product Launch Strategies (14/05/2008)
• Drug Repositioning Strategies (14/05/2008)
• The Future of Biosimilars (14/05/2008)

---